VANTIN Drug Patent Profile

« Back to Dashboard

Which patents cover Vantin, and when can generic versions of Vantin launch?

Vantin is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in VANTIN is cefpodoxime proxetil. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the cefpodoxime proxetil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vantin

A generic version of VANTIN was approved as cefpodoxime proxetil by AUROBINDO PHARMA LTD on June 8^th, 2007.

Summary for VANTIN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	2
Patent Applications:	4,022
DailyMed Link:	VANTIN at DailyMed

Recent Clinical Trials for VANTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington University School of Medicine	N/A
University of Oklahoma	Phase 1

See all VANTIN clinical trials

US Patents and Regulatory Information for VANTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VANTIN	cefpodoxime proxetil	FOR SUSPENSION;ORAL	050675-001	Aug 7, 1992		DISCN	Yes	No
Pfizer	VANTIN	cefpodoxime proxetil	TABLET;ORAL	050674-002	Aug 7, 1992		DISCN	Yes	No
Pfizer	VANTIN	cefpodoxime proxetil	FOR SUSPENSION;ORAL	050675-002	Aug 7, 1992		DISCN	Yes	No
Pfizer	VANTIN	cefpodoxime proxetil	TABLET;ORAL	050674-001	Aug 7, 1992		DISCN	Yes	No

Vantin Market Dynamics and Financial Trajectory: Cefpodoxime Proxetil Patent, Generic, and Commercial Analysis

Last updated: October 1, 2026

Vantin is the U.S. brand name for cefpodoxime proxetil, an orally administered third-generation cephalosporin. Its commercial trajectory has followed the standard lifecycle for an older small-molecule antibiotic: initial branded sales, loss of exclusivity, generic substitution, brand erosion, and migration into a low-price multisource market. Public sources do not report current standalone Vantin revenue. The commercial value now resides primarily in generic cefpodoxime products rather than the Vantin brand.

What is Vantin and how is it used?

Vantin contains cefpodoxime proxetil, an oral prodrug converted to cefpodoxime after absorption. It is approved for selected bacterial infections, including respiratory-tract infections, urinary-tract infections, skin and skin-structure infections, and uncomplicated gonorrhea, subject to labeling limitations and antimicrobial-susceptibility considerations (U.S. Food and Drug Administration [FDA], n.d.-a).

Attribute	Vantin
Active ingredient	Cefpodoxime proxetil
Therapeutic class	Oral third-generation cephalosporin
Dosage forms	Tablets and oral suspension
Original U.S. regulatory pathway	New Drug Application, NDA 50-739
Administration	Oral
Primary commercial market	Generic outpatient anti-infective market
Biologic status	Small molecule
Biosimilar exposure	None
Current commercial structure	Predominantly generic cefpodoxime products

Cefpodoxime is a beta-lactam antibiotic. Like other cephalosporins, it inhibits bacterial cell-wall synthesis. Its use is constrained by bacterial resistance, allergy risk, local prescribing patterns, and antimicrobial-stewardship policies.

What is the FDA regulatory status of Vantin?

Vantin has an FDA approval record under NDA 50-739, but regulatory approval and active commercial distribution are separate issues. A drug can retain an FDA approval history while the branded product is no longer a meaningful commercial competitor.

The FDA label identifies cefpodoxime proxetil tablets in multiple strengths and cefpodoxime proxetil powder for oral suspension. The product was approved for adults and pediatric patients in specific indications, with dosing determined by infection type, age, renal function, and formulation (FDA, n.d.-a).

FDA status and commercial interpretation

Regulatory issue	Assessment
FDA approval history	Established through NDA 50-739
Active ingredient	Cefpodoxime proxetil
FDA pathway	Traditional small-molecule NDA
Orphan-drug status	Not a central commercial feature
Pediatric exclusivity	No current commercial significance identified
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated New Drug Application, or ANDA
Current value driver	Generic supply, contracting, and distribution

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the principal source for current reference-product and generic-equivalence information. Orange Book status should be distinguished from actual pharmacy availability because listed products may not be actively marketed or may have limited distribution (FDA, n.d.-b).

When did Vantin lose exclusivity and why did revenue decline?

Vantin’s financial decline followed the expiration of the relevant small-molecule patent and regulatory exclusivity periods, after which generic manufacturers could enter the market through ANDAs. The precise commercial inflection point was driven by the timing of generic approvals, launch decisions, wholesaler inventory, and payer substitution.

The brand’s revenue trajectory can be summarized as follows:

Lifecycle phase	Market condition	Financial effect
Launch and early adoption	Branded product with limited direct substitution	Higher price and brand-level gross margin
Pre-generic maturity	Established physician awareness and payer coverage	Stable but slowing branded demand
Generic entry	Multiple ANDA applicants and therapeutic substitution	Rapid unit and price erosion
Mature generic market	Commodity procurement and low reimbursement	Low unit economics and fragmented supply
Current phase	Vantin brand has limited strategic relevance	Revenue primarily attributed to generic cefpodoxime

No publicly disclosed financial filing provides a reliable, current, standalone Vantin revenue series. Pfizer and predecessor-company reporting historically grouped products into broader portfolios and therapeutic categories rather than disclosing Vantin revenue separately. Current cefpodoxime sales are also generally reported, if at all, within generic manufacturer portfolios.

The financial trajectory is therefore best assessed through market structure rather than brand revenue. The key event was loss of exclusivity, followed by price compression and substitution.

How many patents protect Vantin and cefpodoxime proxetil?

Vantin is not protected today by a commercially meaningful patent estate comparable to a recently launched specialty drug. The relevant composition, formulation, and manufacturing patents for cefpodoxime proxetil are old small-molecule patents, and any ordinary U.S. patent protection would have expired years ago under the applicable historical patent terms.

The commercial protection profile is better characterized as follows:

Protection category	Current relevance
Active-ingredient patent	Historical protection; expired
Original product patent	Historical protection; expired
Formulation patents	Historical or narrow protection; no material branded barrier identified
Method-of-use patents	No meaningful current exclusivity barrier identified
Pediatric exclusivity	Expired or commercially immaterial
Orphan exclusivity	Not a significant protection mechanism
Manufacturing know-how	Potential operational value, but not a market exclusivity barrier

Cefpodoxime proxetil does not have the patent profile of a complex injectable, long-acting formulation, or biologic. Generic manufacturers can generally compete through conventional oral solid-dose or suspension products, provided they satisfy FDA quality, bioequivalence, chemistry, manufacturing, and controls requirements.

What formulation patents protect Vantin?

Vantin was marketed in oral tablet and oral suspension forms. The primary technical considerations are not current patent exclusivity but product quality and manufacturing execution.

Tablets

Tablet products require control of:

• Cefpodoxime proxetil assay and content uniformity
• Prodrug stability
• Dissolution and bioequivalence
• Particle-size and solid-state properties
• Moisture sensitivity and packaging
• Impurity and degradation profiles

Oral suspension

The suspension presents additional manufacturing and quality requirements:

• Uniform drug distribution after reconstitution
• Sedimentation and redispersibility
• Stability after water addition
• Flavoring and excipient compatibility
• Appropriate storage and beyond-use instructions
• Dose-measurement accuracy

These requirements create regulatory and operational barriers but do not create a durable market monopoly. Formulation complexity is moderate compared with inhaled products, depot injections, liposomal products, or biologics.

Are there Paragraph IV challenges to Vantin?

Paragraph IV litigation is not a current commercial driver for Vantin. Paragraph IV certifications are used by generic applicants challenging listed patents before patent expiry. For an older antibiotic whose relevant patents expired long ago, the principal legal issue has shifted from patent challenge to ordinary ANDA approval, manufacturing compliance, and market participation.

Historically, any Paragraph IV activity would have related to patents listed for cefpodoxime proxetil products in the Orange Book. The 180-day generic exclusivity mechanism could have influenced early market entry if a first applicant successfully challenged a listed patent. That period is no longer the central determinant of Vantin’s economics.

Legal issue	Current impact
Paragraph IV certification	Limited or historical
ANDA approval	Primary route for generic competition
Hatch-Waxman litigation	No current material Vantin-driven case identified
Patent settlement	No current settlement-driven market restriction identified
Patent expiry	Main historical trigger for generic entry
Regulatory enforcement	More relevant than patent litigation

What generic entry risks exist for Vantin?

Generic entry risk is effectively realized rather than prospective. Cefpodoxime has been available from generic manufacturers, making the relevant question the intensity and stability of generic competition.

Competitive pressures

Generic cefpodoxime competes on:

1. Wholesale acquisition cost and reimbursement.
2. Supply reliability.
3. FDA manufacturing history.
4. Product availability in tablets and suspension.
5. Distributor and group-purchasing contracts.
6. Formulary positioning.
7. Shortages or discontinuations among competing suppliers.

The largest commercial risk is price erosion. The principal supply risk is concentration: if only a small number of manufacturers actively market a product, a manufacturing interruption can produce temporary scarcity and improve pricing for remaining suppliers.

Which companies challenge or compete with Vantin?

The competitive landscape includes generic cefpodoxime manufacturers and alternative oral antibiotics. Manufacturer participation changes over time because ANDA holders may discontinue products, transfer approvals, or stop active marketing.

The most relevant competitor groups are:

Competitor group	Examples
Generic cefpodoxime suppliers	ANDA holders and authorized generic distributors
Oral cephalosporins	Cefdinir, cefuroxime axetil, cephalexin
Respiratory alternatives	Amoxicillin, amoxicillin-clavulanate, azithromycin, doxycycline
Urinary-tract alternatives	Nitrofurantoin, trimethoprim-sulfamethoxazole, fluoroquinolones where appropriate
Pediatric liquid alternatives	Amoxicillin-based products and other oral cephalosporin suspensions

The relevant competitor varies by infection, local resistance data, patient allergy, renal function, age, dosing convenience, and payer policy. Cefpodoxime does not compete only against other cephalosporins. It competes against lower-cost antibiotics with stronger guideline positioning in several common outpatient indications.

How strong is the Vantin patent estate?

The current patent estate is weak as a source of exclusivity. Its strength lies in historical product development and regulatory approval, not in enforceable market protection.

Patent-strength assessment

Factor	Rating	Rationale
Remaining composition-of-matter protection	Low	Legacy small-molecule product
Remaining formulation protection	Low	Conventional oral dosage forms
Method-of-use protection	Low	Broad indications and mature clinical use
Manufacturing barriers	Moderate	Quality and process controls remain necessary
Regulatory complexity	Low to moderate	Standard ANDA pathway
Generic substitution risk	High	Mature multisource market
Brand pricing power	Very low	Limited differentiation
Litigation leverage	Very low	No current blocking patent position identified

A generic manufacturer may still face practical barriers involving bioequivalence, impurity control, suspension stability, and manufacturing-site compliance. Those barriers can delay entry for an individual applicant, but they do not protect the Vantin brand from market-wide substitution.

What is the Orange Book status of Vantin?

The Orange Book records FDA-approved products and therapeutic-equivalence information, including reference-listed drugs and approved generic equivalents. Vantin’s strategic importance in the Orange Book is historical. The reference product designation can support ANDA review, but it does not preserve commercial pricing power once multiple therapeutically equivalent generics are available.

Orange Book analysis should distinguish among:

• The reference-listed drug.
• Approved ANDAs.
• Therapeutic-equivalence codes.
• Patent and exclusivity records.
• Active versus discontinued marketing status.

FDA product databases can show approval history even when a branded product has little or no current distribution (FDA, n.d.-b).

What licensing deals affect Vantin?

No major current licensing transaction is a central value driver for Vantin. The product originated from a legacy pharmaceutical development and commercialization structure rather than a current platform licensing model.

Any historical rights involving discovery, formulation, manufacturing, or regional commercialization would have limited present economic significance because the product is mature and genericized. Current commercial rights generally relate to ANDA ownership, contract manufacturing, distribution, or supply arrangements rather than brand licensing.

What is the financial trajectory for Vantin?

Vantin’s financial trajectory is a decline from branded pharmaceutical economics to low-margin generic economics.

Revenue profile

• Branded period: revenue supported by branded pricing, physician familiarity, and protected market access.
• Generic transition: units shifted rapidly to lower-priced equivalents.
• Mature market: price and volume became dependent on contracts, availability, and reimbursement.
• Current position: standalone Vantin revenue is not publicly disclosed and is likely immaterial relative to large pharmaceutical portfolios.

Margin profile

The brand’s gross-margin advantage disappeared after generic competition. Generic cefpodoxime can remain commercially viable because development costs are lower than for an original NDA, but margins depend on manufacturing scale and the number of active suppliers.

Market-size interpretation

Prescription volume does not translate directly into brand revenue. A mature generic antibiotic may retain meaningful unit demand while producing limited manufacturer revenue. Retail prices can also differ significantly among cash-pay, insured, Medicaid, and pharmacy purchasing channels.

What manufacturing and intellectual-property barriers remain?

The principal barriers are operational and regulatory rather than patent-based.

Manufacturers must demonstrate:

• Consistent active-ingredient sourcing.
• Validated production processes.
• Bioequivalence to the reference product.
• Stable tablet and suspension formulations.
• Control of degradation products.
• Compliance with current good manufacturing practices.
• Reliable packaging and labeling.
• Continued FDA inspection compliance.

Cefpodoxime proxetil is not among the most technically difficult generic products. It does not require biologic comparability, sterile injectable manufacturing, device integration, or complex delivery technology. Manufacturing quality and supply continuity remain important, especially for oral suspension products.

What is the outlook for Vantin and cefpodoxime?

The Vantin brand has limited growth potential. The broader cefpodoxime market may remain stable in selected outpatient uses, but growth is constrained by antimicrobial stewardship, generic pricing, resistance concerns, and competition from other oral antibiotics.

The most plausible market outcomes are:

Scenario	Commercial result
Stable generic supply	Continued low-price, moderate-volume market
Supplier consolidation	Temporary price increases and shortage sensitivity
Increased stewardship restrictions	Lower use in empiric prescribing
Brand relaunch	Unlikely to justify premium pricing without differentiation
New formulation	Could improve convenience but would require clinical and commercial investment
Manufacturing disruption	Short-term supply imbalance without restoring durable brand value

Key Takeaways

• Vantin is the legacy brand for cefpodoxime proxetil.
• Its commercial value shifted from branded sales to generic cefpodoxime after loss of exclusivity.
• No current patent estate appears capable of blocking ordinary generic competition.
• Paragraph IV litigation and patent settlements are historical rather than current market drivers.
• Tablets and oral suspension remain the principal dosage forms.
• The product is a small molecule, so biosimilar risk does not apply.
• Current economics depend on generic price competition, supply reliability, reimbursement, and manufacturing compliance.
• Standalone Vantin revenue is not publicly disclosed.
• The brand has low pricing power and limited prospects for a commercially attractive relaunch.

FAQs about Vantin market dynamics

Is Vantin still sold in the United States?

Cefpodoxime proxetil remains available through generic products, while the commercial importance of the Vantin brand is limited. FDA approval records should not be treated as proof of active branded distribution.

Is cefpodoxime a generic antibiotic?

Yes. Cefpodoxime proxetil is available from generic manufacturers through FDA-approved ANDAs.

Does Vantin have biosimilars?

No. Vantin is a small-molecule antibiotic, not a biologic. Its competitive products are generics, not biosimilars.

Can a pharmaceutical company relaunch Vantin at a premium price?

A premium relaunch would face substantial resistance because therapeutically equivalent generic cefpodoxime is available. A new formulation or delivery system would be required to create meaningful differentiation.

What determines cefpodoxime generic profitability?

Profitability depends on manufacturing scale, active-ingredient costs, supplier concentration, reimbursement, contract access, product availability, and the number of active generic competitors.

References

1. U.S. Food and Drug Administration. (n.d.-a). Vantin (cefpodoxime proxetil) prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. National Library of Medicine. (n.d.). Cefpodoxime proxetil drug labeling. DailyMed.

4. U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. FDA.

5. U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application approvals and therapeutic equivalence. FDA.